ASCO 2014: Making and Breaking Cancer Drugs
Multiple abstracts support growing investor enthusiasm for Big Pharma's immuno-oncology efforts.
Regeneron Earnings: Is Now the Time to Buy?
Regeneron’s Eylea sales slowed down slightly during the first quarter, although the company beat estimates on both the top and bottom lines.
Rising R&D Expenses Drive ImmunoGen's Q3 Loss Significantly Higher
Higher research and development costs coupled with an absence of milestone and license fee revenue sends ImmunoGen's loss markedly higher.
Abbott Labs Earnings: Still Marking Time
Abbot's long-term potential is masked by its weak near-term growth.
Why Zogenix, ImmunoGen, and voxeljet Are Today's 3 Best Stocks
The Beige Book release and key economic data pumps up the S&P 500 while Zogenix, ImmunoGen, and voxeljet lead individual stocks to the upside.
Why ImmunoGen Inc. Shares Took Flight
ImmunoGen shares bounce after receiving fresh coverage from Wall Street. Find out what shareholders should really be focused on following this new rating.
This Forgotten Pharma Could Be a Hit for Your Portfolio
Roche combines a very deep oncology pipeline with some of the best growth and margins in Pharma
Biotech Is Officially in a Bear Market. Is It Time to Panic?
The SPDR S&P Biotech ETF is down 27% in just the past six weeks placing it squarely in bear market territory. Is it time for investors to duck and cover?
Here's What's Behind Puma's Crash
Puma Biotech (PBYI) is working on a promising breast cancer drug, but its shares are dropping sharply. Here's what you need to know about neratinib and why Puma investors got nervous.